Lord, Abbett & Co
ACAD icon

Lord, Abbett & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

Lord, Abbett & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-787,028
Closed -$33.7M – 625
2019
Q4 		$33.7M Buy
787,028
+170,419
+28% +$7.41M 0.11% 285
2019
Q3 		$22.2M Buy
+616,609
New +$18.7M 0.08% 386
2017
Q2 		– Sell
-253,673
Closed -$8.72M – 873
2017
Q1 		$8.72M Sell
253,673
-25,800
-9% -$911K 0.03% 637
2016
Q4 		$8.06M Sell
279,473
-885,811
-76% -$23.4M 0.02% 631
2016
Q3 		$37.1M Sell
1,165,284
-1,026,169
-47% -$34.8M 0.11% 286
2016
Q2 		$71.1M Buy
2,191,453
+2,126,453
+3,271% +$71.2M 0.22% 133
2016
Q1 		$1.82M Sell
65,000
-530,723
-89% -$11.6M 0.01% 836
2015
Q4 		$21.2M Sell
595,723
-98,506
-14% -$3.47M 0.06% 412
2015
Q3 		$23M Sell
694,229
-273,869
-28% -$11.4M 0.07% 382
2015
Q2 		$40.5M Buy
968,098
+584,339
+152% +$22.6M 0.11% 307
2015
Q1 		$12.5M Sell
383,759
-905,850
-70% -$31.1M 0.03% 578
2014
Q4 		$40.9M Sell
1,289,609
-488,609
-27% -$13.9M 0.1% 275
2014
Q3 		$44M Buy
1,778,218
+678,797
+62% +$15.9M 0.11% 259
2014
Q2 		$24.8M Buy
1,099,421
+200,368
+22% +$4.18M 0.06% 473
2014
Q1 		$21.9M Sell
899,053
-86,892
-9% -$2.2M 0.05% 483
2013
Q4 		$24.6M Sell
985,945
-716,073
-42% -$16.9M 0.05% 473
2013
Q3 		$46.8M Sell
1,702,018
-418,652
-20% -$8.75M 0.11% 277
2013
Q2 		$38.5M Buy
+2,120,670
New +$29.2M 0.09% 340

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Lord, Abbett & Co's ACAD Position: Q1 2020 in Review

Lord, Abbett & Co sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 787,028 shares — an estimated $33.7M sold.

Lord, Abbett & Co first reported a position in ACAD in Q2 2013 and held it in 18 quarters. The position peaked at $71.1M in Q2 2016. 245 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

  • Lord, Abbett & Co reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Lord, Abbett & Co sold 787,028 Acadia Pharmaceuticals shares in Q1 2020, an estimated $33.7M.
  • Lord, Abbett & Co first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Lord, Abbett & Co's Acadia Pharmaceuticals position peaked at $71.1M in Q2 2016.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Lord, Abbett & Co's 13F filing for Q1 2020, filed 14 May 2020.